Search results
Moderna COVID vaccine sales plummet 91 percent - The Boston Globe
The Boston Globe· 6 days agoSales of Moderna’s COVID-19 vaccine plunged 91 percent from the previous year for the first quarter...
Fauci, other top health officials receive Moderna Covid-19 vaccine on camera
AOL· 1 day agoFauci, director of the National Institute of Allergy and Infectious Diseases, received the shot...
BioNTech Revenue Falls Sharply on Reduced Covid Vaccine Sales
Barrons.com· 2 days agoFEATURE U.S.-listed shares of BioNTech were falling Monday after the German company that partnered...
Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To...
Benzinga via Yahoo Finance· 7 days agoOn Wednesday, Pfizer Inc. (NYSE:PFE) reported first-quarter adjusted EPS of $0.82, down 33% year...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
AOL· 6 days agoThe dark days of the pandemic are finally in the past for most of us—and that seems to be reflected in the earnings for Moderna, whose revenue is dependent on sales of its COVID< ...
Pfizer Inc (PFE) Q1 2024 Earnings Call Transcript Highlights: Navigating Post-COVID Challenges ...
GuruFocus.com via Yahoo Finance· 6 days agoPfizer Inc (NYSE:PFE) is navigating challenges in the post-COVID market, which continues to affect its financial performance. The company's gross margin ...
Why Pfizer Stock Blasted More Than 6% Higher Today
Motley Fool via Yahoo Finance· 7 days agoThe Covid effect not as damaging as feared For its first quarter, Pfizer reported before market open, the pharmaceutical giant took in just under $14.9...
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
Motley Fool via Yahoo Finance· 4 days agoBourla said in the Q1 call that the company "will make a decision for future plans" after seeing the...
Moderna Puts Up Big Quarterly Beat; Could Shares Break Out?
Investor's Business Daily· 6 days agoModerna (MRNA) beat Wall Street's first-quarter expectations Thursday. The Covid vaccine maker came...
Pfizer's Stock Is a Buy. Here Are Six Reasons Why.
Motley Fool via Yahoo Finance· 6 days agoPrevnar: The pneumococcal vaccine should continue being a cash cow for the drugmaker despite potential competition from Merck's vaccine V116 in the adult...